As ADCs become one of the most active areas of pharma M&A (there were more than $50 billion in ADC-focused transactions in 2023-2024), the quality of the FTO analysis on both the acquirers and the targets IP estates is a critical diligence factor
In humans, GLP-1 is not only damaged by DPP-4, but also by neutral endopeptidase 24.11 (NEP 24.11), and the main catalytic sites are Glu 27 Phe 28 and Trp 31 Leu 32
Avraham SA, Hossein J, Somri F, Hawash N, Hochman O
Additionally, GLP-1RAs ameliorate DPN through various mechanisms, including the inhibition of inflammation, oxidative stress, and extracellular matrix remodeling, while simultaneously improving neural structure, function, and energy metabolism [11, 12, 30, 79,80,81,82,83,84,85,86]